People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Other Health Care, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RESTOR3D, Inc. | — | Other Health Care | Series C | $239.2M | $522.3M | 2024 |
| Osteal Therapeutics, Inc. | — | Pharmaceuticals | Series C | $127.5M | $87.1M | 2018 |
| Vergent Bioscience, Inc. | — | Biotechnology | Series B | $57.0M | $77.3M | 2022 |
| Bio2 Technologies, Inc. | — | Biotechnology | Series A | $14.4M | $16.4M | 2016 |
Douglas Kohrs at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Kohrs on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gary Jacobs | 1 | 11 |
| David Thompson | 1 | 10 |
| Andrew Miller | 1 | 8 |
| Renee Ryan | 1 | 6 |
| Kenneth Gall | 1 | 5 |
| Kurt Jacobus | 1 | 5 |
| John Santini | 1 | 5 |
| Ryan Egeland | 1 | 4 |
| Ken Gall | 1 | 4 |
| Raymond Wong | 1 | 4 |
| Adam Wallen | 1 | 3 |
| Rushu Luo | 1 | 3 |
| ANDREW SUMMERS | 1 | 3 |
| JAMES STUBBS | 1 | 3 |
| Michael Porter | 1 | 3 |
| William Rhoda | 1 | 2 |
| Cheryl Blanchard | 1 | 2 |
| Jude Paganelli | 1 | 2 |
| David Cash | 1 | 2 |
| Cambre Kelly | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.